RNAi company list from the free issue.
Alnylam
Cambridge, Mass.
Private
John Maraganore, president, CEO, & director;
Tom Ulich, senior vice president of R&D
Developing RNAi-based drugs with a focus
on viral, oncologic, metabolic, CNS, and
autoimmune diseases.
Ambion
Austin, Texas
Private
Matt Winkler, CEO & CSO;
Bruce Leander, president
Sells RNAi oligos, research products,
and reagents.
Atugen
Berlin
Private
Klaus Giese, CSO; Thomas Christély,
COO & CFO
Developing RNAi-based drugs with a focus
on cancer; also provides drug discovery
and validation services.
Benitec
Brisbane, Australia
Public
(Australia)
John McKinley, chairman & CEO; Ken Reed,
director of research & technology
Developing RNAi-based drugs for HIV/AIDS,
cancer, hepatitis, diabetes, cardiomyopathies,
autoimmune, and CNS diseases.
BD Biosciences
Clontech
Palo Alto, Calif.
Unit of publicly
held Becton,
Dickinson
Sailaja Kuchibhatla, vice president of
business development
Sells instrumentation, research products,
and reagents.
Cenix BioScience
Dresden, Germany
Private Christophe Echeverri, CEO & CSO
Sells siRNAs through a collaboration with
Ambion; also provides drug discovery and
validation services.
CytRx
Los Angeles
Public
Steven Kriegsman, president & CEO; David
Haen, director of business development
Developing RNAi-based drugs for obesity,
type II diabetes, and ALS.
Dharmacon
Lafayette, Colo.
Private Stephen Scaringe, co-chairman & CSO
Sells RNAi oligos, research products, and
reagents.
Genta
Berkeley Heights, NJ
Public
Raymond Warrell, chairman & CEO;
Robert Klem, vice president of discovery &
CTO
Developing RNAi-based cancer drugs.
Intradigm
Rockville, Md.
Private
John Spears, chairman & CEO;
Martin Woodle, CSO
Developing RNAi-based cancer drugs.
Nucleonics
Malvern, Pa.
Private
Robert Towarnicki, president & CEO; C.
Satishchandran, vice president of R&D; Cathy
Pachuk, senior director of biological research
Developing RNAi-based drugs for
hepatitis B and C.
Proligo
Boulder, Colo.
Unit of publicly
held (Germany)
Degussa
Klaus Puell, CEO; Bruno Poddevin, vice
president of Primers and Probes division
Sells RNAi oligos, instrumentation, research
products, and reagents.
Promega
Madison, Wis.
Private
William Linton, president, & CEO; Richard Schifreen,
director of technology and market development
Sells instrumentation, research products, and
reagents.
Qiagen
Venlo, Netherlands
Public
Metin Colpan, CEO & managing director;
Detlev Riesner, supervisory board chairman
& supervisory director
Sells RNAi oligos, research products,
and reagents.
Sequitur
Natick, Mass.
Private
Tod Woolf, president & CEO; Margaret
Taylor, vice president of research
Developing RNAi-based drugs, with a focus
on hepatic insufficiency, RSV, asthma,
breast cancer; also provides drug discovery
and validation services, as well as research
products and reagents.
Sirna
Boulder, Colo.
Public
Howard Robin, president & CEO; Nassim
Usman, CSO & vice president of R&D
Developing RNAi-based drugs for hepatitis
C and age-related macular degeneration. |
